Found: 15
Select item for more details and to access through your institution.
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 828, doi. 10.1007/s10637-017-0551-z
- By:
- Publication type:
- Article
Nicotine and cotinine increases the brain penetration of saquinavir in rat.
- Published in:
- Journal of Neurochemistry, 2010, v. 115, n. 6, p. 1495, doi. 10.1111/j.1471-4159.2010.07054.x
- By:
- Publication type:
- Article
Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood-brain barrier integrity.
- Published in:
- Journal of Neurochemistry, 2010, v. 115, n. 2, p. 515, doi. 10.1111/j.1471-4159.2010.06948.x
- By:
- Publication type:
- Article
Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations.
- Published in:
- International Journal of Medical Sciences, 2021, v. 18, n. 16, p. 3718, doi. 10.7150/ijms.65040
- By:
- Publication type:
- Article
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti‐EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 9, p. 1225, doi. 10.1002/jcph.1418
- By:
- Publication type:
- Article
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Oncology Combination Dose‐Finding Study Design for Targeted and Immuno‐Oncology Therapies.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 1, p. 29, doi. 10.1002/cpt.3085
- By:
- Publication type:
- Article
Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 1, p. 23, doi. 10.1007/s00280-020-04202-0
- By:
- Publication type:
- Article
Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
- Published in:
- Neuro-Oncology, 2016, v. 18, n. 1, p. 27, doi. 10.1093/neuonc/nov164
- By:
- Publication type:
- Article
INFLUENCE OF DRUG DELIVERY ON THERAPEUTIC BENEFIT IN GBM–CDK4 AND MDM2 INHIBITOR COMPARISON IN FLANK VERSUS ORTHOTOPIC MODELS AND COMPARISON OF BRAIN PENETRANT VERSUS IMPENETRANT PI3K/MTOR INHIBITORS.
- Published in:
- Neuro-Oncology, 2014, v. 16, n. suppl_3, p. iii33, doi. 10.1093/neuonc/nou208.40
- By:
- Publication type:
- Article